Brief: Abvc Biopharma Provides Abv-1601 Update On Phase I Site Initiation Visit Conducted At Cedars-Sinai Medical Center
10/04/2023 14:34
April 10 (Reuters) - ABVC Biopharma Inc ABVC.O :
* ABVC BIOPHARMA PROVIDES ABV-1601 UPDATE ON PHASE I SITE
INITIATION VISIT CONDUCTED AT CEDARS-SINAI MEDICAL CENTER (CSMC)
* ABVC BIOPHARMA - EXPECTS TO INITIATE PHASE II STUDY OF
ABV-1601
IN Q4 OF 2023 AND THEN COMPARE RESULTS TO WELLBUTRIN XL
Source text for Eikon: ID:nGNX3ndsVj
Further company coverage: ABVC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ABVC Biopharma
See all newsBrief: ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon
Brief: Abvc Biopharma Inc Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: ABVC Biopharma Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements
Brief: ABVC Biopharma Inc On March 5, Leeds Chow Resigns As CFO Of Abvc Biopharma
Brief: ABVC Biopharma Secures $200,000 In First Cash Licensing Payment From Oncology Products Partner